STOCK TITAN

NeuroMetrix to Introduce Quell® Fibromyalgia at the American College of Rheumatology 2022 Annual Meeting

Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Neutral)
Tags
Rhea-AI Summary

NeuroMetrix, Inc. (Nasdaq: NURO) will present its innovative device, Quell Fibromyalgia, at the ACR Convergence 2022 from November 12 to 14 in Philadelphia. This wearable neuromodulation technology is the first FDA-authorized device aimed at alleviating fibromyalgia symptoms. Fibromyalgia affects approximately 5 to 15 million U.S. adults, characterized by chronic pain and fatigue. Quell Fibromyalgia, part of NeuroMetrix's prescription wearable neurotherapeutics, supports patients with high pain sensitivity, offering a potential breakthrough in treatment options.

Positive
  • Quell Fibromyalgia is the first FDA-authorized device specifically for fibromyalgia management.
  • Fibromyalgia impacts a significant portion of the adult population, indicating a large market opportunity.
  • The device utilizes advanced neuromodulation technology with a proprietary microchip.
Negative
  • Product usage is limited to prescription only, which may restrict market access.
  • Uncertainty exists around insurance coverage for the device, potentially affecting sales.

WOBURN, Mass., Nov. 08, 2022 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) will introduce Quell Fibromyalgia at the American College of Rheumatology Annual Meeting, ACR Convergence 2022, on November 12 – 14 in Philadelphia, Pennsylvania. Quell Fibromyalgia is a wearable neuromodulation technology that is the first and only FDA authorized medical device to help reduce the symptoms of fibromyalgia. Conference attendees are encouraged to visit the Company’s booth #1745 for a demonstration and to review prescribing details for fibromyalgia patients.

Fibromyalgia is a chronic condition characterized by generalized pain, fatigue, poor sleep, memory and concentration impairments, mood disorders and other disabling symptoms. The prevalence of fibromyalgia is estimated to be 2 to 6 percent of the U.S. adult population (5 to 15 million people).

Quell Fibromyalgia emerged from the NeuroMetrix pipeline of prescription wearable neurotherapeutics, two of which received FDA Breakthrough Device Designation: fibromyalgia and chemotherapy induced peripheral neuropathy (CIPN).

"We are pleased to contribute to the unmet need for safe and effective treatments for people with fibromyalgia," said Shai N. Gozani, M.D., Ph.D., Chief Executive Officer, NeuroMetrix. "This conference is an opportunity for us to exchange information with rheumatologists who are managing patients with fibromyalgia."

Quell Fibromyalgia Indications

Quell Fibromyalgia is a transcutaneous electrical nerve stimulation (TENS) device indicated as an aid for reducing the symptoms of fibromyalgia in adults with high pain sensitivity. The device may be used during sleep.

Limitations

The sale, distribution, and use of Quell Fibromyalgia is restricted to prescription use in accordance with 21 CFR 801.109. The product labeling should be reviewed for a complete list of contraindications, precautions and warnings.

About Quell Technology

Quell is an advanced, non-invasive, neuromodulation technology that is covered by 23 U.S. utility patents. It is the only wearable neuromodulator that is enabled by a proprietary microchip to provide precise, high-power nerve stimulation in a form factor the size of a credit card. Quell utilizes position and motion sensing to automatically adjust stimulation for an optimal user experience both day and night. The device supports Bluetooth® low energy (BLE) to communicate with mobile apps for multiple smartphone and smartwatch platforms.

About NeuroMetrix

NeuroMetrix is an innovation-driven company with a mission to improve individual and population health through novel medical devices and technology solutions for neurological disorders and pain syndromes. The Company has three commercial products. DPNCheck® is a diagnostic device that provides rapid, point-of-care detection of peripheral neuropathies. ADVANCE® is a diagnostic device that provides automated, in-office nerve conduction studies for the evaluation of focal neuropathies. Quell® Fibromyalgia is a wearable neuromodulator that is the first and only FDA-authorized medical device to help reduce the symptoms of fibromyalgia. For more information, visit www.neurometrix.com.

Source: NeuroMetrix, Inc.

Thomas T. Higgins
SVP and Chief Financial Officer
781-314-2761
neurometrix.ir@neurometrix.com


FAQ

What is Quell Fibromyalgia by NeuroMetrix?

Quell Fibromyalgia is a wearable neuromodulation device by NeuroMetrix, FDA-authorized to help reduce fibromyalgia symptoms.

When will NeuroMetrix present Quell Fibromyalgia?

NeuroMetrix will present Quell Fibromyalgia at the ACR Convergence 2022 from November 12 to 14 in Philadelphia.

What is the significance of Quell Fibromyalgia?

Quell Fibromyalgia represents a breakthrough as the first FDA-authorized device specifically designed for fibromyalgia management.

How many people in the U.S. are affected by fibromyalgia?

Fibromyalgia affects an estimated 5 to 15 million adults in the U.S., around 2 to 6 percent of the population.

NeuroMetrix, Inc.

NASDAQ:NURO

NURO Rankings

NURO Latest News

NURO Stock Data

8.01M
1.59M
25.45%
3.01%
2.08%
Medical Devices
Surgical & Medical Instruments & Apparatus
Link
United States of America
WALTHAM